CA1072413A - Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante - Google Patents

Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante

Info

Publication number: CA1072413A
Authority: CA; Canada
Prior art keywords: component; forming composition; gel forming; gelling; gel
Prior art date: 1976-07-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA256,878A

Other languages

English (en)

Inventor

Abraham Cantor

Murray W. Winicov

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

WEST LABORATORIES

Original Assignee

WEST LABORATORIES

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-07-13

Filing date

1976-07-13

Publication date

1980-02-26

1976-07-13 Application filed by WEST LABORATORIES filed Critical WEST LABORATORIES

1976-07-13 Priority to CA256,878A priority Critical patent/CA1072413A/fr

1980-02-26 Application granted granted Critical

1980-02-26 Publication of CA1072413A publication Critical patent/CA1072413A/fr

Status Expired legal-status Critical Current

Links

229920001983 poloxamer Polymers 0.000 title abstract description 56
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 title abstract description 35
229960000502 poloxamer Drugs 0.000 title abstract description 22
239000000203 mixture Substances 0.000 claims abstract description 78
239000003349 gelling agent Substances 0.000 claims abstract description 30
239000007788 liquid Substances 0.000 claims abstract description 24
238000010790 dilution Methods 0.000 claims abstract description 13
239000012895 dilution Substances 0.000 claims abstract description 13
230000000051 modifying effect Effects 0.000 claims description 25
229920000642 polymer Polymers 0.000 claims description 11
239000008346 aqueous phase Substances 0.000 claims description 7
239000002537 cosmetic Substances 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
239000000463 material Substances 0.000 claims description 5
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
230000000069 prophylactic effect Effects 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 3
229920001451 polypropylene glycol Polymers 0.000 claims description 3
229940124597 therapeutic agent Drugs 0.000 claims description 3
238000010792 warming Methods 0.000 claims description 3
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
239000012459 cleaning agent Substances 0.000 claims description 2
HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims description 2
239000000077 insect repellent Substances 0.000 claims description 2
230000000749 insecticidal effect Effects 0.000 claims description 2
229920001515 polyalkylene glycol Polymers 0.000 claims description 2
239000000306 component Substances 0.000 claims 37
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
230000036760 body temperature Effects 0.000 abstract description 14
239000003607 modifier Substances 0.000 abstract description 11
231100000252 nontoxic Toxicity 0.000 abstract description 5
230000003000 nontoxic effect Effects 0.000 abstract description 5
210000001124 body fluid Anatomy 0.000 abstract description 4
239000010839 body fluid Substances 0.000 abstract description 4
230000007704 transition Effects 0.000 abstract description 4
239000000499 gel Substances 0.000 description 71
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000000243 solution Substances 0.000 description 13
239000004094 surface-active agent Substances 0.000 description 10
229920001992 poloxamer 407 Polymers 0.000 description 7
239000007787 solid Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
239000003599 detergent Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
-1 alkyl phenol Chemical compound 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
241001465754 Metazoa Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
230000003028 elevating effect Effects 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
229920002359 Tetronic® Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000002689 soil Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cosmetics (AREA)
Medicinal Preparation (AREA)

CA256,878A 1976-07-13 1976-07-13 Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante Expired CA1072413A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA256,878A CA1072413A (fr)	1976-07-13	1976-07-13	Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA256,878A CA1072413A (fr)	1976-07-13	1976-07-13	Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante

Publications (1)

Publication Number	Publication Date
CA1072413A true CA1072413A (fr)	1980-02-26

Family

ID=4106420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA256,878A Expired CA1072413A (fr)	1976-07-13	1976-07-13	Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante

Country Status (1)

Country	Link
CA (1)	CA1072413A (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362713A (en)	1980-07-25	1982-12-07	Johnson & Johnson Products Inc.	Salts of maleic acid copolymers as dental plaque barrier agents
US4364924A (en)	1980-07-25	1982-12-21	Johnson & Johnson Products, Inc.	Alkali metal salts of poly(vinylbenzoic acid) as dental plaque barrier agents
US4474753A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Topical drug delivery system utilizing thermosetting gels
US4474751A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Ophthalmic drug delivery system utilizing thermosetting gels
US4474752A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
US4478822A (en) *	1983-05-16	1984-10-23	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
EP0126684A3 (en) *	1983-05-16	1986-02-05	Merck & Co. Inc.	Drug delivery system utilizing thermosetting gels
WO1986000813A1 (fr) *	1984-07-27	1986-02-13	Schering Aktiengesellschaft	Compositions pharmaceutiques renfermant des gels
US4861760A (en) *	1985-10-03	1989-08-29	Merck & Co., Inc.	Ophthalmological composition of the type which undergoes liquid-gel phase transition
WO1990012576A1 (fr) *	1989-04-25	1990-11-01	The Green Cross Corporation	Composition liquide de prostaglandine
EP0439335A1 (fr) *	1990-01-24	1991-07-31	Colgate-Palmolive Company	Composition pour l'application topique
EP0386960A3 (fr) *	1989-03-07	1991-10-23	American Cyanamid Company	Compositions pharmaceutiques utilisables comme véhicules de délivrance d'un médicament et/ou comme pansements pour blessures
WO1993001286A3 (fr) *	1991-06-28	1993-04-01	Massachusetts Inst Technology	Therapie localisee utilisant des oligonucleotides
EP0481600A3 (en) *	1990-10-16	1993-04-21	American Cyanamid Company	Materials useful in human and veterinary medicine
US5279660A (en) *	1988-05-24	1994-01-18	Berol Nobel Stenungsund Ab	Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system
US5593974A (en) *	1991-06-28	1997-01-14	Massachusetts Institute Of Technology	Localized oligonucleotide therapy
EP0955063A1 (fr) *	1998-04-01	1999-11-10	Basf Aktiengesellschaft	Utilisations de compositions aqueuses dans des médicaments pour une administration sous-cutanée ou intramusculaire
US8802116B2 (en)	2003-02-27	2014-08-12	Novasel Australia Pty. Ltd.	Poloxamer emulsion preparations
WO2016123125A1 (fr) *	2015-01-27	2016-08-04	The Johns Hopkins University	Formulations d'hydrogel hypotoniques pour le transport amélioré d'agents actifs au niveau de surfaces muqueuses
US10568975B2 (en)	2013-02-05	2020-02-25	The Johns Hopkins University	Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US12005089B2 (en)	2014-12-15	2024-06-11	The Johns Hopkins University	CVS transplantation for treatment of bacterial vaginosis

1976
- 1976-07-13 CA CA256,878A patent/CA1072413A/fr not_active Expired

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362713A (en)	1980-07-25	1982-12-07	Johnson & Johnson Products Inc.	Salts of maleic acid copolymers as dental plaque barrier agents
US4364924A (en)	1980-07-25	1982-12-21	Johnson & Johnson Products, Inc.	Alkali metal salts of poly(vinylbenzoic acid) as dental plaque barrier agents
US4474753A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Topical drug delivery system utilizing thermosetting gels
US4474751A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Ophthalmic drug delivery system utilizing thermosetting gels
US4474752A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
US4478822A (en) *	1983-05-16	1984-10-23	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
EP0126684A3 (en) *	1983-05-16	1986-02-05	Merck & Co. Inc.	Drug delivery system utilizing thermosetting gels
WO1986000813A1 (fr) *	1984-07-27	1986-02-13	Schering Aktiengesellschaft	Compositions pharmaceutiques renfermant des gels
US4861760A (en) *	1985-10-03	1989-08-29	Merck & Co., Inc.	Ophthalmological composition of the type which undergoes liquid-gel phase transition
US5279660A (en) *	1988-05-24	1994-01-18	Berol Nobel Stenungsund Ab	Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system
EP0386960A3 (fr) *	1989-03-07	1991-10-23	American Cyanamid Company	Compositions pharmaceutiques utilisables comme véhicules de délivrance d'un médicament et/ou comme pansements pour blessures
WO1990012576A1 (fr) *	1989-04-25	1990-11-01	The Green Cross Corporation	Composition liquide de prostaglandine
GR910100036A (en) *	1990-01-24	1992-06-25	Colgate Palmolive Co	Topical composition
EP0439335A1 (fr) *	1990-01-24	1991-07-31	Colgate-Palmolive Company	Composition pour l'application topique
EP0481600A3 (en) *	1990-10-16	1993-04-21	American Cyanamid Company	Materials useful in human and veterinary medicine
WO1993001286A3 (fr) *	1991-06-28	1993-04-01	Massachusetts Inst Technology	Therapie localisee utilisant des oligonucleotides
US5593974A (en) *	1991-06-28	1997-01-14	Massachusetts Institute Of Technology	Localized oligonucleotide therapy
EP0955063A1 (fr) *	1998-04-01	1999-11-10	Basf Aktiengesellschaft	Utilisations de compositions aqueuses dans des médicaments pour une administration sous-cutanée ou intramusculaire
US8802116B2 (en)	2003-02-27	2014-08-12	Novasel Australia Pty. Ltd.	Poloxamer emulsion preparations
US10568975B2 (en)	2013-02-05	2020-02-25	The Johns Hopkins University	Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US11633350B2 (en)	2014-02-23	2023-04-25	The Johns Hopkins University	Hypotonic microbicidal formulations and methods of use
US12005089B2 (en)	2014-12-15	2024-06-11	The Johns Hopkins University	CVS transplantation for treatment of bacterial vaginosis
CN107635545A (zh) *	2015-01-27	2018-01-26	约翰霍普金斯大学	用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂
US10485757B2 (en)	2015-01-27	2019-11-26	The Johns Hopkins University	Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
WO2016123125A1 (fr) *	2015-01-27	2016-08-04	The Johns Hopkins University	Formulations d'hydrogel hypotoniques pour le transport amélioré d'agents actifs au niveau de surfaces muqueuses
US11426345B2 (en)	2015-01-27	2022-08-30	The Johns Hopkins University	Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces

Legal Events

Date	Code	Title	Description
1997-02-26	MKEX	Expiry

Publication	Publication Date	Title
CA1072413A (fr)	1980-02-26	Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante
US5519059A (en)	1996-05-21	Antifungal formulation
Schmolka	1972	Artificial skin I. Preparation and properties of pluronic F‐127 gels for treatment of burns
US3867533A (en)	1975-02-18	Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US2484637A (en)	1949-10-11	Powdered ointment base of methyl cellulose and sorbitol
CZ25793A3 (en)	1993-10-13	Pharmaceutical mixtures of phlorphenicol
JPH06256121A (ja)	1994-09-13	改良型グリフォセート除草剤組成物
CZ199297A3 (cs)	1998-01-14	Plnící materiál pro měkkou želatinovou farmaceutickou dávkovou formu
KR20000075561A (ko)	2000-12-15	국소용 니메설라이드 겔 시스템
LT4585B (lt)	1999-12-27	Vietinis anestetikas išoriniam vartojimui
JP2770400B2 (ja)	1998-07-02	農薬固型製剤
JP4195178B2 (ja)	2008-12-10	消炎鎮痛外用剤
CN104994852A (zh)	2015-10-21	透皮的杀寄生虫制剂
ES2276425T3 (es)	2007-06-16	Composicion bilogicamente activa.
JPH0364483B2 (fr)	1991-10-07
EP0113397B1 (fr)	1989-04-19	Compositions de gel anthelmintique et procédé de leur préparation à températures ambiantes
JPS6231975B2 (fr)	1987-07-11
JPH02200611A (ja)	1990-08-08	自己乳化性皮膚用クリーム
JP2571390B2 (ja)	1997-01-16	獣医用治療剤
JP2562913B2 (ja)	1996-12-11	透明ゲル状組成物
KR100214714B1 (ko)	1999-08-02	신규한 국소마취제 함유 겔제제
SU576115A1 (ru)	1977-10-15	Способ получени прополисовой мази "пропоцеум"
JP4463337B2 (ja)	2010-05-19	軟膏製剤
JP2003516943A (ja)	2003-05-20	皮膚適用による寄生性昆虫の幼虫の処理のための流体殺昆虫剤調合物
JPH024563B2 (fr)	1990-01-29